Treatment of agitation and aggression in bipolar mania: Efficacy of quetiapine

Peter F Buckley, Björn Paulsson, Martin Brecher

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania. Methods: Four double-blind, randomized, controlled trials were conducted using similar protocols; 407 patients with bipolar I mania were randomized to quetiapine monotherapy (200-800 mg/day) or placebo for 12 weeks, and 402 patients were randomized to quetiapine (200-800 mg/day) or placebo in combination with lithium (Li) or divalproex (DVP) for 3 or 6 weeks. Measurements of agitation included the Positive and Negative Syndrome Scale (PANSS) Activation subscale, PANSS Supplemental Aggression Risk subscale scores, and Young Mania Rating Scale (YMRS) items relevant to agitation. Results: Initial reductions in both the PANSS Activation and PANSS Supplemental Aggression Risk subscale scores were noted by Day 4 with quetiapine and placebo. The reduction in PANSS Activation subscale scores was significantly greater with quetiapine monotherapy than placebo first at Day 21 (- 3.5 versus - 1.4, P < 0.001) and also at Day 84 (- 4.8 versus - 1.2, P < 0.001). The improvement in PANSS Supplemental Aggression Risk subscale score was significantly greater with quetiapine monotherapy than placebo by Day 14 (P < 0.01) and all time points thereafter including Day 21 (- 4.0 versus - 1.8, P < 0.001) and Day 84 (- 5.6 versus - 1.7, P < 0.001). In combination therapy, the mean improvement in PANSS Activation subscale score at Day 21 was numerically but not significantly different with QTP +Li/DVP than PBO + Li/DVP (- 4.2 versus - 3.2, P = 0.087). The mean PANSS Supplemental Aggression Risk subscale scores were significantly improved at Day 21 with QTP + Li/DVP versus PBO + Li/DVP (- 5.05 versus - 3.69, P < 0.05). Conclusions: Quetiapine is an effective and appropriate treatment choice in managing agitation and aggression associated with bipolar mania.

Original languageEnglish (US)
JournalJournal of Affective Disorders
Volume100
Issue numberSUPPL. 1
DOIs
StatePublished - May 31 2007

Fingerprint

Aggression
Bipolar Disorder
Valproic Acid
Lithium
Placebos
Therapeutics
Quetiapine Fumarate
Double-Blind Method
Randomized Controlled Trials

Keywords

  • Aggression
  • Agitation
  • Bipolar disorder
  • Quetiapine

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Treatment of agitation and aggression in bipolar mania : Efficacy of quetiapine. / Buckley, Peter F; Paulsson, Björn; Brecher, Martin.

In: Journal of Affective Disorders, Vol. 100, No. SUPPL. 1, 31.05.2007.

Research output: Contribution to journalArticle

Buckley, Peter F ; Paulsson, Björn ; Brecher, Martin. / Treatment of agitation and aggression in bipolar mania : Efficacy of quetiapine. In: Journal of Affective Disorders. 2007 ; Vol. 100, No. SUPPL. 1.
@article{bdb6a96a6da54fe8b4e86e3276337360,
title = "Treatment of agitation and aggression in bipolar mania: Efficacy of quetiapine",
abstract = "Objective: Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania. Methods: Four double-blind, randomized, controlled trials were conducted using similar protocols; 407 patients with bipolar I mania were randomized to quetiapine monotherapy (200-800 mg/day) or placebo for 12 weeks, and 402 patients were randomized to quetiapine (200-800 mg/day) or placebo in combination with lithium (Li) or divalproex (DVP) for 3 or 6 weeks. Measurements of agitation included the Positive and Negative Syndrome Scale (PANSS) Activation subscale, PANSS Supplemental Aggression Risk subscale scores, and Young Mania Rating Scale (YMRS) items relevant to agitation. Results: Initial reductions in both the PANSS Activation and PANSS Supplemental Aggression Risk subscale scores were noted by Day 4 with quetiapine and placebo. The reduction in PANSS Activation subscale scores was significantly greater with quetiapine monotherapy than placebo first at Day 21 (- 3.5 versus - 1.4, P < 0.001) and also at Day 84 (- 4.8 versus - 1.2, P < 0.001). The improvement in PANSS Supplemental Aggression Risk subscale score was significantly greater with quetiapine monotherapy than placebo by Day 14 (P < 0.01) and all time points thereafter including Day 21 (- 4.0 versus - 1.8, P < 0.001) and Day 84 (- 5.6 versus - 1.7, P < 0.001). In combination therapy, the mean improvement in PANSS Activation subscale score at Day 21 was numerically but not significantly different with QTP +Li/DVP than PBO + Li/DVP (- 4.2 versus - 3.2, P = 0.087). The mean PANSS Supplemental Aggression Risk subscale scores were significantly improved at Day 21 with QTP + Li/DVP versus PBO + Li/DVP (- 5.05 versus - 3.69, P < 0.05). Conclusions: Quetiapine is an effective and appropriate treatment choice in managing agitation and aggression associated with bipolar mania.",
keywords = "Aggression, Agitation, Bipolar disorder, Quetiapine",
author = "Buckley, {Peter F} and Bj{\"o}rn Paulsson and Martin Brecher",
year = "2007",
month = "5",
day = "31",
doi = "10.1016/j.jad.2007.02.005",
language = "English (US)",
volume = "100",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of agitation and aggression in bipolar mania

T2 - Efficacy of quetiapine

AU - Buckley, Peter F

AU - Paulsson, Björn

AU - Brecher, Martin

PY - 2007/5/31

Y1 - 2007/5/31

N2 - Objective: Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania. Methods: Four double-blind, randomized, controlled trials were conducted using similar protocols; 407 patients with bipolar I mania were randomized to quetiapine monotherapy (200-800 mg/day) or placebo for 12 weeks, and 402 patients were randomized to quetiapine (200-800 mg/day) or placebo in combination with lithium (Li) or divalproex (DVP) for 3 or 6 weeks. Measurements of agitation included the Positive and Negative Syndrome Scale (PANSS) Activation subscale, PANSS Supplemental Aggression Risk subscale scores, and Young Mania Rating Scale (YMRS) items relevant to agitation. Results: Initial reductions in both the PANSS Activation and PANSS Supplemental Aggression Risk subscale scores were noted by Day 4 with quetiapine and placebo. The reduction in PANSS Activation subscale scores was significantly greater with quetiapine monotherapy than placebo first at Day 21 (- 3.5 versus - 1.4, P < 0.001) and also at Day 84 (- 4.8 versus - 1.2, P < 0.001). The improvement in PANSS Supplemental Aggression Risk subscale score was significantly greater with quetiapine monotherapy than placebo by Day 14 (P < 0.01) and all time points thereafter including Day 21 (- 4.0 versus - 1.8, P < 0.001) and Day 84 (- 5.6 versus - 1.7, P < 0.001). In combination therapy, the mean improvement in PANSS Activation subscale score at Day 21 was numerically but not significantly different with QTP +Li/DVP than PBO + Li/DVP (- 4.2 versus - 3.2, P = 0.087). The mean PANSS Supplemental Aggression Risk subscale scores were significantly improved at Day 21 with QTP + Li/DVP versus PBO + Li/DVP (- 5.05 versus - 3.69, P < 0.05). Conclusions: Quetiapine is an effective and appropriate treatment choice in managing agitation and aggression associated with bipolar mania.

AB - Objective: Agitation and aggression are potentially disruptive and dangerous features of bipolar mania. This analysis evaluated the effects of quetiapine on agitation and aggression in patients with bipolar I mania. Methods: Four double-blind, randomized, controlled trials were conducted using similar protocols; 407 patients with bipolar I mania were randomized to quetiapine monotherapy (200-800 mg/day) or placebo for 12 weeks, and 402 patients were randomized to quetiapine (200-800 mg/day) or placebo in combination with lithium (Li) or divalproex (DVP) for 3 or 6 weeks. Measurements of agitation included the Positive and Negative Syndrome Scale (PANSS) Activation subscale, PANSS Supplemental Aggression Risk subscale scores, and Young Mania Rating Scale (YMRS) items relevant to agitation. Results: Initial reductions in both the PANSS Activation and PANSS Supplemental Aggression Risk subscale scores were noted by Day 4 with quetiapine and placebo. The reduction in PANSS Activation subscale scores was significantly greater with quetiapine monotherapy than placebo first at Day 21 (- 3.5 versus - 1.4, P < 0.001) and also at Day 84 (- 4.8 versus - 1.2, P < 0.001). The improvement in PANSS Supplemental Aggression Risk subscale score was significantly greater with quetiapine monotherapy than placebo by Day 14 (P < 0.01) and all time points thereafter including Day 21 (- 4.0 versus - 1.8, P < 0.001) and Day 84 (- 5.6 versus - 1.7, P < 0.001). In combination therapy, the mean improvement in PANSS Activation subscale score at Day 21 was numerically but not significantly different with QTP +Li/DVP than PBO + Li/DVP (- 4.2 versus - 3.2, P = 0.087). The mean PANSS Supplemental Aggression Risk subscale scores were significantly improved at Day 21 with QTP + Li/DVP versus PBO + Li/DVP (- 5.05 versus - 3.69, P < 0.05). Conclusions: Quetiapine is an effective and appropriate treatment choice in managing agitation and aggression associated with bipolar mania.

KW - Aggression

KW - Agitation

KW - Bipolar disorder

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=34249291226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249291226&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2007.02.005

DO - 10.1016/j.jad.2007.02.005

M3 - Article

C2 - 17376537

AN - SCOPUS:34249291226

VL - 100

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - SUPPL. 1

ER -